Feb 26, 2026 · “ADAPT OCULUS is the first registrational study specifically designed to evaluate a targeted therapy for ocular myasthenia gravis,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of . We embrace the power of the collective – together we are better. At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to . The name argenx comes from the ancient myth of the Argonauts – one of the first stories on record recognizing the power of the team rather than one hero. The Argonauts set out in a small boat on a .
At argenx, we are redefining how a biotech company can advance science and deliver innovative treatments. We're enabling new ways of working with partners, patients and each other. January 12, 2026 argenx Highlights 2026 Strategic Priorities January 6, 2026 argenx to Present at 44th Annual J.P. Morgan Healthcare Conference January 5, 2026 argenx Announces Leadership . At argenx, our commitment to ESG is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company.
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them. By combining llama-derived V regions with fully human Fc regions, argenx creates a library of human-like antibodies that can be tested across multiple epitopes to find the right balance of potency, safety, . Feb 23, 2026 · What does it look like to work at argenx? Here’s a snapshot into how we stay connected to the patients inspiring our work, collaborate with colleagues around the world, and drive innovation .
Apr 25, 2008 · On May 5, 2017, we transferred the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1, 2017.
- Argenx | argenx Announces Positive Topline Results from Phase 3.
- “ADAPT OCULUS is the first registrational study specifically designed to evaluate a targeted therapy for ocular myasthenia gravis,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of.
- argenx Highlights 2026 Strategic Priorities January 6, 2026 argenx to Present at 44th Annual J.P.
Argenx | Products - Approved for use in the United States. This indicates that "Argenx (ARGX) withdraws Phase 2 efgartigimod study in Guillain-Barré syndrome" should be tracked with broader context and ongoing updates.
Argenx | Innovation - The Science of Collaboration. For readers, this helps frame potential impact and what to watch next.
FAQ
What happened with Argenx (ARGX) withdraws Phase 2 efgartigimod study in Guillain-Barré syndrome?
What does it look like to work at argenx?
Why is Argenx (ARGX) withdraws Phase 2 efgartigimod study in Guillain-Barré syndrome important right now?
Company Profile - argenx Annual Report 2024.
What should readers monitor next?
Watch for official updates, verified data changes, and follow-up statements from primary sources.
